Compare CGNX & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CGNX | PCVX |
|---|---|---|
| Founded | 1981 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 6.1B |
| IPO Year | 1989 | 2020 |
| Metric | CGNX | PCVX |
|---|---|---|
| Price | $39.43 | $45.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 7 |
| Target Price | $46.45 | ★ $105.00 |
| AVG Volume (30 Days) | ★ 1.7M | 1.2M |
| Earning Date | 02-11-2026 | 02-24-2026 |
| Dividend Yield | ★ 0.86% | N/A |
| EPS Growth | ★ 27.63 | N/A |
| EPS | ★ 0.65 | N/A |
| Revenue | ★ $971,705,000.00 | N/A |
| Revenue This Year | $9.46 | N/A |
| Revenue Next Year | $7.09 | N/A |
| P/E Ratio | $60.65 | ★ N/A |
| Revenue Growth | ★ 10.23 | N/A |
| 52 Week Low | $22.67 | $27.66 |
| 52 Week High | $49.76 | $93.77 |
| Indicator | CGNX | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 62.31 | 49.29 |
| Support Level | $37.55 | $44.57 |
| Resistance Level | $38.81 | $47.72 |
| Average True Range (ATR) | 0.79 | 1.73 |
| MACD | 0.45 | -0.08 |
| Stochastic Oscillator | 99.19 | 36.33 |
Cognex Corp provides machine vision products that help automate manufacturing processes. The firm's products include vision software, vision systems, vision sensors, and ID products. Vision software combines vision tools with a customer's cameras and peripheral equipment and can help with several vision tasks, including part location, identification, measurement, and robotic guidance. Vision systems combine a camera, processor, and vision software into a single package. Vision sensors deliver simple, low-cost solutions for common vision applications, such as checking the size of parts. ID products read codes that have been applied to items during the manufacturing process. Cognex generates the maximum proportion of its sales in the United States and Europe.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.